News and Insights
NHS and London’s private hospitals join forces to fast-track new heart disease technology
November 17, 2026
UCLPartners will co-lead a UK-first innovation programme, bringing together private healthcare providers and the NHS, to test new ways to prevent, detect and treat heart disease, diabetes and obesity, so that new proven technologies can rapidly reach NHS patients.New technologies that could help prevent heart attacks and strokes will be tested in independent hospitals and clinics in Harley Street Health District, as part of a first-of-its-kind innovation programme designed to get the most promising ideas to NHS patients across London more quickly. The Frontier Innovation for Cardiometabolic Disease Programme, backed by £10 million from UK Research and Innovation’s Local Innovation Partnerships Fund, supported by the Mayor of London, brings together partners across London to accelerate the development, validation and adoption of innovations for heart disease, diabetes and obesity. The £5 million scale-up and adoption arm of the programme, led by UCLPartners and Harley Street Health District, with support from the wider London Health Innovation Networks, will enable technology companies to rapidly gather real-world evidence of how well their products work, bringing proven technologies into NHS services, and improving outcomes for people across London. This is the first time a national public health programme has drawn on the scale and patient reach of London’s independent healthcare sector in this way. Cardiovascular disease causes one in four deaths in London, around 13,000 a year. Around 70% of it is preventable, yet more than 500,000 Londoners are living with high blood pressure without knowing it. In the UK, many promising health technologies never reach patients. They stall because companies struggle to gather the evidence the NHS and other healthcare providers need to adopt them. This programme gives those companies a faster route to that evidence. The programme will focus on a range of technologies across cardiometabolic disease prevention, from identifying people at risk earlier to interventions that help reduce risk, support healthier lifestyles and manage conditions such as high blood pressure and high cholesterol. It will prioritise innovations that can reduce inequalities in heart health and will generate evidence across London’s diverse communities. The Frontier Innovation for Cardiometabolic Disease Programme aims to leverage up to £300 million in private investment and create up to 1,000 high-value jobs in London. It will engage more than 100 companies, give tailored support to at least 20 and help at least five breakout-stage companies prove their products and scale them through the NHS. Dr Chris Laing, Chief Executive Officer, UCLPartners, said: “This partnership is about drawing on London’s world leading assets to bring the most effective innovations to the NHS, so patients across the city can benefit faster from new technologies. By harnessing the agility of private hospitals to test innovations quickly, and the scale of the NHS to adopt what works, we can ensure the best care is available to patients with cardiovascular disease, improving outcomes and experiences for the thousands of people living with this disease” Mark Kildea, Chief Executive of The Howard de Walden Estate, said: “Forty per cent of London’s independent healthcare happens in Harley Street Health District, and we have one of the greatest concentrations of clinical expertise anywhere in the world. Many of the world-leading consultants who practise here also work in the NHS. That gives us a real opportunity to put the independent sector to work on one of London’s most pressing health challenges. “Through this programme, companies will be able to test their ideas with real patients and build the evidence the NHS needs. Most importantly, it will help good ideas reach patients sooner.” |